Business Wire

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab ...
Business Wire

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan (Dato-DXd) plus durvalumab (Arm 7) showed ...
Healio

Datopotamab deruxtecan fails to extend OS vs. chemotherapy in advanced breast cancer

Please provide your email address to receive an email when new articles are posted on . Datopotamab deruxtecan failed to extend OS vs. chemotherapy for adults with advanced breast cancer, according to ...
Nasdaq

Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US ...
Monthly Prescribing Reference

FDA Grants Priority Review to Datopotamab Deruxtecan for Metastatic TNBC

Datopotamab deruxtecan significantly improves overall survival compared with chemotherapy in previously untreated metastatic TNBC. The Food and Drug Administration (FDA) has accepted for Priority ...
Monthly Prescribing Reference

First-Line Datopotamab Deruxtecan Improves PFS, OS in Metastatic TNBC

Findings showed datopotamab deruxtecan significantly improved PFS and OS vs chemotherapy. Topline data were announced from a phase 3 trial evaluating datopotamab deruxtecan-dlnk as a first-line ...
Pharmabiz

Datopotamab deruxtecan shows clinically meaningful OS improvement vs. chemotherapy in patients with advanced nonsquamous NSCLC in TROPION-Lung01 phase III trial

High-level overall survival (OS) results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favoured datopotamab ...
The American Journal of Managed Care

TROPION-Breast01, TROPION-Lung01 Demonstrate PFS Benefit of Datopotamab Deruxtecan in Metastatic Breast Cancer, NSCLC

Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention ...